Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study.

MLA

de la Cruz-Merino, Luis, et al. “Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study.” Cancers, vol. 13, no. 21, Nov. 2021, p. 5432. EBSCOhost, https://doi.org/10.3390/cancers13215432.

APA

de la Cruz-Merino, L., Gion, M., Cruz-Jurado, J., Quiroga, V., Andrés, R., Moreno, F., Alonso-Romero, J. L., Ramos, M., Holgado, E., Cortés, J., López-Miranda, E., Henao-Carrasco, F., Palazón-Carrión, N., Rodríguez, L. M., Ceballos, I., Casas, M., Benito, S., Chiesa, M., Bezares, S., & Caballero, R. (2021). Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study. Cancers, 13(21), 5432. https://doi.org/10.3390/cancers13215432

Chicago

de la Cruz-Merino, Luis, María Gion, Josefina Cruz-Jurado, Vanesa Quiroga, Raquel Andrés, Fernando Moreno, Jose L. Alonso-Romero, et al. 2021. “Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study.” Cancers 13 (21): 5432. doi:10.3390/cancers13215432.